Email Alert | RSS

Journal of Peking University(Health Sciences) ›› 2018, Vol. 50 ›› Issue (6): 981-985. doi: 10.19723/j.issn.1671-167X.2018.06.007

• Article • Previous Articles     Next Articles

Value of serum matrix metalloproteinase 3 in the assessment of early rheumatoid arthritis

Meng-ke LIU1,2,3,Lu-chen WANG1,2,3,Fan-lei HU1,2,△()   

  1. 1. Department of Rheumatology and Immunology, Peking University People’s Hospital & Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135) Beijing 100044, China
    2. State Key Laboratory of Natural and Biomimetic Drugs,Peking University School of Pharmaceutical Sciences,Beijing 100191, China
    3. Nanchang University Queen Mary School, Nanchang 330000, China
  • Received:2018-07-23 Online:2018-12-18 Published:2018-12-18
  • Contact: Fan-lei HU E-mail:fanleihu@bjmu.edu.cn
  • Supported by:
    Supported by the National Natural Science Foundation of China(81671604);Supported by the National Natural Science Foundation of China(81302554);Supported by the National Natural Science Foundation of China(31530020);Supported by the National Natural Science Foundation of China(81501396);Supported by the National Natural Science Foundation of China(81871281);the Beijing Nova Program(Z181100006218044);Peking University Clinical Medcine + X Project PKU2018LCXQ003(PKU2018LCXQ003)

RICH HTML

 26   

PDF (PC)

463

Abstract:

Objective: To investigate the expression level of serum matrix metalloproteinase 3 (MMP3) in early rheumatoid arthritis (ERA) patients with normal C-reaction protein (CRP) or erythrocyte sedimentation rate (ESR), and the significance in disease assessment.Methods:In the study, 133 cases of early RA patients, 25 osteoarthritis (OA) patients and 60 healthy controls in Peking University People’s Hospital from 2011 to 2015 were included. The RA patients were further divided into 4 groups according to levels of CRP and ESR: 88 patients with increased CRP and increased ESR, 15 patients with normal CRP and normal ESR, 17 patients with normal CRP but increased ESR, and 13 patients with increased CRP but normal ESR. All the clinical information of the patients was collected, and the serum MMP3 levels of both patients and healthy controls were detected by enzyme-linked immune sorbent assay (ELISA).Results:The serum MMP3 level of RA patients with normal CRP and/or normal ESR [(72.89±6.34) μg/L] was obviously higher than that of OA patients [(42.87±4.14) μg/L](P=0.002) and healthy controls [(31.62±2.88) μg/L](P<0.001). The serum MMP3 levels of the patients with normal CRP and normal ESR[(47.04±9.64) μg/L] were higher than those of the healthy controls, and there was statistical significance between the two groups (P<0.05). The serum MMP3 levels of the patients with increased CRP but normal ESR [(94.18±9.11) μg/L] and the patients with normal CRP but increased ESR [(79.42±10.60) μg/L] were both higher than those of the OA patients and healthy controls, and there was obvious statistical difference (P<0.05). In the early RA patients with normal CRP and/or normal ESR, the serum MMP3 level was positively correlated with the CRP level (r=0.336,P=0.024). The positive rate of MMP3 in the patients with normal CRP and/or normal ESR was 44.44%, higher than the positive rate of CRP (28.89%) and the positive rate of ESR (37.78%).In these early RA patients, the positive rate was 52.94% in the patients with normal CRP but increased ESR and 53.85% in the patients with increased CRP but normal ESR.Conclusion:The detection of the serum MMP3 level was significant in the assessment of early RA patients within 2-year duration who had normal CRP or ESR value.

Key words: Matrix metalloproteinase 3, Early rheumatoid arthritis, C-reaction protein, Erythrocyte sedimentation rate, Assessment value

CLC Number: 

  • R593.22

Table 1

Comparison of CRP, ESR, MMP3 positive rate in CRP normal and/or ESR normal early RA patients"

Items Total cases Positive cases Positive rate/%
MMP3 45 20 44.44
CRP 45 13 28.89
ESR 45 17 37.78

Table 2

Comparison of the positive rate of MMP3 vs. ESR under normal CRP, or MMP3 vs. CRP under normal ESR"

Items Normal CRP Normal ESR
ESR MMP3 CRP MMP3
Total cases 32 32 28 28
Positive cases 17 13 13 11
Positive rate/% 53.13 40.63 46.43 39.29

Table 3

Comparison of CRP, ESR, MMP3 positive rate in patients with the duration less than 6 months"

Items Total cases Positive cases Positive rate/%
MMP3 55 44 80.00
CRP 55 42 76.36
ESR 55 45 81.82

Table 4

Comparison of MMP3 positive rate among groups of RA patients"

Group Total cases MMP3 positive Positive
rate/%
Normal CRP and/or normal ESR 45 20 44.44
Normal CRP increased ESR 17 9 52.94
Increased CRP normal ESR 13 7 53.85
Normal CRP normal ESR 15 4 26.67

Figure 1

Comparison of MMP3 levels in early RA patients of different CRP, ESR grouping, OA patients and healthy controlA, increased CRP increased ESR; B, normal CRP normal ESR; C, normal CRP increased ESR; D, increased CRP normal ESR; OA, osteoarthritis; HC, healthy control."

Table 5

Correlation between MMP3 level and clinical characteristics"

Items Increased CRP increased ESR Normal CRP and/or normal ESR
r P r P
CRP 0.125 0.254 0.336 0.024*
ESR 0.318 0.003# 0.069 0.651
IgA -0.100 0.376 0.099 0.531
IgG 0.237 0.035* -0.112 0.478
IgM 0.107 0.346 -0.259 0.097
RF -0.245 0.053 -0.122 0.435
anti-CCP -0.293 0.012* -0.008 0.964
Tender joint count 0.149 0.181 -0.074 0.628
Swollen joint count 0.153 0.167 -0.023 0.883
DAS28 0.248 0.025* -0.017 0.916

Table 6

Comparison of IgA, IgG, IgM levels in early RA patients with different CRP, ESR grouping"

Groups IgA/(g/L) IgG/(g/L) IgM/(g/L)
Increased CRP increased ESR 3.28±1.37 14.98±4.77 1.25±0.72
Increased CRP normal ESR 2.51±1.16 14.21±6.54 0.72±0.26*
Normal CRP increased ESR 3.80±1.67 14.99±4.08 1.43±0.77
Normal CRP normal ESR 2.44±0.87* 13.27±2.49 0.98±0.39
[1] Smolen JS, Aletaha D , McInnes IB. Rheumatoid arthritis[J]. Lancet, 2016,388(10055):2023-2038.
doi: 10.1016/S0140-6736(16)30173-8
[2] 葛均波, 徐永健 . 内科学[M]. 8版. 北京: 人民卫生出版社, 2014: 808-814.
[3] Mittal R, Patel AP, Debs LH , et al. Intricate functions of matrix metalloproteinases in physiological and pathological conditions[J]. J Cell Physiol, 2016,231(12):2599-2621.
doi: 10.1002/jcp.25430 pmid: 27187048
[4] 耿学丽, 武英伟, 孙常铭 , 等. 类风湿关节炎患者基质金属蛋白酶-3的检测[J]. 广东医学, 2016,37(4):555-557.
[5] Hiura K, Iwaki-Egawa S, Kawashima T , et al. The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic citrullina-ted peptide antibody-negative patients with recent-onset undifferentiated arthritis[J]. Rheumatol Int, 2013,33(9):2309-2314.
doi: 10.1007/s00296-013-2716-1 pmid: 23503938
[6] 马剑达, 王晓莹, 莫颖倩 , 等. 血清基质金属蛋白酶3评价类风湿关节炎患者病情活动的价值[J]. 中华医学杂志, 2015,95(47):3823-3828.
doi: 10.3760/cma.j.issn.0376-2491.2015.47.006
[7] Lee YC, Hackett J, Frits M , et al. Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia[J]. Rheumatology (Oxford), 2016,55(4):640-648.
doi: 10.1093/rheumatology/kev388 pmid: 4795537
[8] Ma JD, Wei XN, Zheng DH , et al. Continuously elevated serum matrix metalloproteinase-3 for 3-6 months predict one-year radiographic progression inrheumatoid arthritis: a prospective cohort study[J]. Arthritis Res Ther, 2015,14(17):289-302.
[9] Ainola MM, Mandelin JA, Liljestrom MP , et al. Pannus invasionand cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1β[J]. Clin Exp Rheumatol, 2005,23(5):644-650.
[10] Takeshita M, Kuno A, Suzuki K , et al. Alteration of matrix metalloproteinase-3O-glycan structure as a biomarker fordisease activity of rheumatoid arthritis[J]. Arthritis Res Ther, 2016,18(1):112-121.
doi: 10.1186/s13075-016-1013-2 pmid: 4875599
[11] Houseman M, Potter C, Marshall N , et al. Baseline serum MMP-3 levels in patients with rheumatoid arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up[J]. Arthritis Res Ther, 2012,14(1):30-36.
doi: 10.1186/ar3734 pmid: 3392825
[12] Shiozawa K, Yamane T, Murata M , et al. MMP-3 as a predictor for structural remission in RA patients treated with MTX mono-therapy[J]. Arthritis Res Ther, 2016,18(1):55-64.
doi: 10.1186/s13075-016-0948-7 pmid: 4769545
[13] Urata Y, Uesato R, Tanaka D , et al. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 study[J]. Ann Rheum Dis, 2012,71(4):534-540.
doi: 10.1136/annrheumdis-2011-200108 pmid: 22021897
[14] 孔卓, 吴俊, 张海文 , 等. 血清基质金属蛋白酶3与类风湿关节炎的相关性研究[J]. 标记免疫分析与临床, 2014,21(6):636-639.
doi: 10.11748/bjmy.issn.1006-1703.2014.06.004
[15] 李立新, 蔡蓓, 廖竞宇 , 等. 血清基质金属蛋白酶3对类风湿性关节炎患者骨关节损伤和疗效评估的价值[J]. 细胞与分子免疫学杂志, 2013,29(9):966-969
[16] 史睿, 韩玲, 陈慕芝 , 等. MMP-3、TIMP-1及HCgp-39在早期RA患者血清中的变化及意义[J]. 检验医学与临床, 2017,14(3):325-327.
[1] Jia jia XU,Yan WANG,He SUN,Ru lin JIA,Xue wu ZHANG,Yang MENG,Li li REN,Xiao lin SUN. Clinical significance of detection of soluble interleukin 2 receptor alpha chain in the assessment of rheumatoid arthritis disease activity [J]. Journal of Peking University(Health Sciences), 2018, 50(6): 975-980.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 456 -458 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 125 -128 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 135 -140 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 158 -161 .
[5] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 217 -220 .
[6] . [J]. Journal of Peking University(Health Sciences), 2009, 41(1): 52 -55 .
[7] . [J]. Journal of Peking University(Health Sciences), 2009, 41(1): 109 -111 .
[8] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 297 -301 .
[9] . [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 599 -601 .
[10] . [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 516 -520 .
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd